BioCardia Inc./$BCDA
1D1W1MYTD1Y5YMAX
Capital at risk
About BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
- Ticker
- $BCDA
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 19
- Headquarters
- Sunnyvale, United States
- Website
- www.biocardia.com
BioCardia Inc. Metrics
BasicAdvanced
$18M
-
-$0.74
0.49
-
Price and volume
Market cap
$18M
Beta
0.49
52-week high
$1.80
52-week low
$0.75
Average daily volume
250K
Financial strength
Current ratio
2.091
Quick ratio
2.018
Total debt to equity
0.109
Profitability
EBITDA (TTM)
-7.377
Management effectiveness
Return on assets (TTM)
-134.97%
Return on equity (TTM)
-1,803.19%
Valuation
Price to book
6.49
Price to tangible book (TTM)
6.49
Price to free cash flow (TTM)
-1.541
Free cash flow yield (TTM)
-64.91%
Free cash flow per share (TTM)
-0.759
Growth
Earnings per share change (TTM)
-64.18%
3-year earnings per share growth (CAGR)
-58.33%
10-year earnings per share growth (CAGR)
-48.58%
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.